CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively
low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic …

MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression …

Background Isatuximab is a monoclonal antibody that binds a specific epitope on the human
CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous …

The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab
and isatuximab, has significantly impacted the management of patients with multiple …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of
migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed …

Although the treatment of relapsed/refractory multiple myeloma has improved dramatically
over the past decade, the disease remains incurable; therefore, additional therapies are …

This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/
dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Patients …

Isatuximab (isatuximab-irfc; Sarclisa®) is an IgG1 monoclonal antibody that binds to the
glycoprotein CD38 expressed on the surface of haematopoietic and tumour cells. It is being …

Treatment for relapsed/refractory multiple myeloma (RRMM) remains an unmet need.
Isatuximab, an anti-CD38 monoclonal antibody has shown efficacy and tolerability as a …